Functional homomers and heteromers of dopamine D 2Land D 3 receptors co-exist at the cell surface

Journal of Biological Chemistry

Volumn 287, Issue 12, 2012, Pages 8864-8878

  Pou, Chantevy ^a   La Cour, Clotilde Mannoury ^b   Stoddart, Leigh A ^a,c   Millan, Mark J ^b   Milligan, Graeme ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b INSTITUT DE RECHERCHES SERVIER   (France)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLTRANSFERASE; CELL SURFACES; COMPLEX MIXTURE; COVALENT LABELING; G PROTEIN; N-TERMINALS; PARKINSON DISEASE; PEPTIDE EPITOPES; STEADY STATE; TIME-RESOLVED FLUORESCENCE;

DISEASES; ENERGY TRANSFER; NEUROPHYSIOLOGY;

CELL MEMBRANES;

CHEMICAL COMPOUND; DOPAMINE 2 LONG RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; HETEROMER; HOMOMER; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; CELL SURFACE; CELLULAR DISTRIBUTION; CHEMICAL MODIFICATION; HUMAN; HUMAN CELL; MOLECULAR CLONING; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; STEADY STATE;

CELL LINE; CELL MEMBRANE; DIMERIZATION; DOPAMINE; HUMANS; PROTEIN BINDING; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3;

EID: 84858607942     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M111.326678     Document Type: Article

References (61)

1. Gardner, E. L. (2011) Addiction and brain reward and antireward pathways. Adv. Psychosom. Med. 30, 22-60
2. Schetz, J. A., and Sibley, D. R. (2007) in Handbook of Contemporary Neuropharmacology (Sibley, D. R., Hanin, I., Kuhar, M. J., and Skolnik, P., eds) pp. 221-256, John Wiley & Sons, Inc., New York
3. 3 receptors are elevated after 9 or 11 months chronic haloperidol treatment. Influence of withdrawal period. Synapse 40, 137-144
4. 3 receptor antagonists as therapeutic agents. Drug Discov. Today 10, 917-925
5. Millan, M. J., Maiofiss, L., Cussac, D., Audinot, V., Boutin, J. A., and Newman-Tancredi, A. (2002) Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J. Pharmacol. Exp. Ther. 303, 791-804 (Pubitemid 35231256)
6. 2 receptor density ratio in the caudate-putamen. Synapse 64, 449-459
7. Perreault, M. L., O'Dowd, B. F., and George, S. R. (2011) Dopamine receptor homooligomers and heterooligomers in schizophrenia. CNS Neurosci. Ther. 17, 52-57
8. Milligan, G., and McGrath, J. C. (2009) GPCR theme editorial. Br. J. Pharmacol. 158, 1-4
9. 2 receptor dimer formation. Evidence from ligand binding. J. Biol. Chem. 276, 22621-22629
10. 2 dopamine receptor homodimerization is mediated by multiple sites of interaction, including an intermolecular interaction involving transmembrane domain 4. Biochemistry 42, 11023-11031
11. 2 receptors form higher order oligomers at physiological expression levels. EMBO J. 27, 2293-2304
12. Han, Y., Moreira, I. S., Urizar, E., Weinstein, H., and Javitch, J. A. (2009) Allosteric communication between protomers of dopamine class A GPCR dimers modulates activation. Nat. Chem. Biol. 5, 688-695
13. Albizu, L., Cottet, M., Kralikova, M., Stoev, S., Seyer, R., Brabet, I., Roux, T., Bazin, H., Bourrier, E., Lamarque, L., Breton, C., Rives, M. L., Newman, A., Javitch, J., Trinquet, E., Manning, M., Pin, J. P., Mouillac, B., and Durroux, T. (2010) Time-resolved FRET between GPCR ligands reveals oligomers in native tissues. Nat. Chem. Biol. 6, 587-594
14. 2 receptor dimerization. Mol. Brain 3, 25
15. 2 receptor negative cooperativity for dopamine binding. A receptor dimer-based analysis. Synapse 64, 566-569
16. 4 receptor oligomerization. Contribution to receptor biogenesis. FEBS J. 278, 1333-1344
17. 3 receptor dimers and tetramers in brain and transfected cells. J. Biol. Chem. 272, 29229-29237
18. Maggio, R., Aloisi, G., Silvano, E., Rossi, M., and Millan, M. J. (2009) Heterodimerization of dopamine receptors. New insights into functional and therapeutic significance. Parkinsonism Relat. Disord. 15, S2-S7
19. 2 receptor heteromer signaling pathway in the brain. Emerging physiological relevance. Mol. Brain 4, 26
20. q/11-coupled dopamine receptors. An uncharted role for dopamine. Trends Pharmacol. Sci. 28, 551-555
21. 2 heterodimers by the antiparkinsonian agents, S32504, pramipexole, and ropinirole. J. Neurochem. 87, 631-641
22. 3 receptors. potential role of heterodimer formation. Parkinsonism Relat. Disord. 14, S139-S144
23. 3 receptors. Potential role of heterodimer formation. J. Neurochem. 102, 1410-1424
24. 3 receptor heteromers. Pharmacological properties and therapeutic significance. Curr. Opin. Pharmacol. 10, 100-107
25. Maurel, D., Comps-Agrar, L., Brock, C., Rives, M. L., Bourrier, E., Ayoub, M. A., Bazin, H., Tinel, N., Durroux, T., Prézeau, L., Trinquet, E., and Pin, J. P. (2008) Cell-surface protein-protein interaction analysis with time-resolved FRET and snap-tag technologies. Application to GPCR oligomerization. Nat. Methods 5, 561-567 (Pubitemid 351761765)
26. Milligan, G., Parenty, G., Stoddart, L. A., and Lane, J. R. (2007) Novel pharmacological applications of G-protein-coupled receptor-G protein fusions. Curr. Opin. Pharmacol. 7, 521-526 (Pubitemid 47560218)
27. 2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning. Neuron 49, 603-615
28. 1 receptors assessed via N-terminal SNAP and CLIP-tagging. Br. J. Pharmacol. 162, 1439-1452
29. i3. Mol. Pharmacol. 71, 1349-1359
30. 3 dopamine receptors. J. Pharmacol. Exp. Ther. 325, 319-330
31. 1 receptor generates a unique complex in which both protomers are regulated by orexin A. J. Biol. Chem. 286, 37414-37428
32. Burt, A. R., Carr, I. C., Mullaney, I., Anderson, N. G., and Milligan, G. (1996) Agonist activation of p42 and p44 mitogen-activated protein kinases following expression of the mouse δ-opioid receptor in Rat-1 fibroblasts. Effects of receptor expression levels and comparisons with G-protein activation. Biochem. J. 320, 227-235
33. Carrillo, J. J., Pediani, J., and Milligan, G. (2003) Dimers of class A G protein-coupled receptors function via agonist-mediated trans-activation of associated G proteins. J. Biol. Chem. 278, 42578-42587 (Pubitemid 37310531)
34. 2A. J. Biol. Chem. 276, 14027-14036
35. Milligan, G. (2004) G protein-coupled receptor dimerization. Function and ligand pharmacology. Mol. Pharmacol. 66, 1-7
36. 1-adrenoceptors. Biochem. Soc. Trans. 32, 847-850
37. Pfeiffer, M., Koch, T., Schröder, H., Laugsch, M., Höllt, V., and Schulz, S. (2002) Heterodimerization of somatostatin and opioid receptors cross-modulates phosphorylation, internalization, and desensitization. J. Biol. Chem. 277, 19762-19772 (Pubitemid 34967492)
38. Baragli, A., Alturaihi, H., Watt, H. L., Abdallah, A., and Kumar, U. (2007) Heterooligomerization of human dopamine receptor 2 and somatostatin receptor 2. Co-immunoprecipitation and fluorescence resonance energy transfer analysis. Cell. Signal. 19, 2304-2316 (Pubitemid 47361686)
39. Margeta-Mitrovic, M., Jan, Y. N., and Jan, L. Y. (2001) Function of GB1 and GB2 subunits in G protein coupling of GABA(B) receptors. Proc. Natl. Acad. Sci. U.S.A. 98, 14649-14654 (Pubitemid 33121446)
40. Alvarez-Curto, E., Pediani, J. D., and Milligan, G. (2010) Applications of fluorescence and bioluminescence resonance energy transfer to drug discovery at G protein-coupled receptors. Anal. Bioanal. Chem. 398, 167-180
41. 3H]spiperone binding to rat brain regions. Proc. Natl. Acad. Sci. U.S.A. 78, 2620-2624
42. 3 receptors. Eur. J. Pharmacol. 666, 43-52
43. Hern, J. A., Baig, A. H., Mashanov, G. I., Birdsall, B., Corrie, J. E., Lazareno, S., Molloy, J. E., and Birdsall, N. J. (2010) Formation and dissociation of M1 muscarinic receptor dimers seen by total internal reflection fluorescence imaging of single molecules. Proc. Natl. Acad. Sci. U.S.A. 107, 2693-2698
44. Dorsch, S., Klotz, K. N., Engelhardt, S., Lohse, M. J., and Bünemann, M. (2009) Analysis of receptor oligomerization by FRAP microscopy. Nat. Methods 6, 225-230
45. Kasai, R. S., Suzuki, K. G., Prossnitz, E. R., Koyama-Honda, I., Nakada, C., Fujiwara, T. K., and Kusumi, A. (2011) Full characterization of GPCR monomer-dimer dynamic equilibrium by single molecule imaging. J. Cell Biol. 192, 463-480
46. O'Dowd, B. F., Ji, X., Alijaniaram, M., Nguyen, T., and George, S. R. (2011) Separation and reformation of cell surface dopamine receptor oligomers visualized in cells. Eur. J. Pharmacol. 658, 74-83
47. Gupta, A., Mulder, J., Gomes, I., Rozenfeld, R., Bushlin, I., Ong, E., Lim, M., Maillet, E., Junek, M., Cahill, C. M., Harkany, T., and Devi, L. A. (2010) Increased abundance of opioid receptor heteromers after chronic morphine administration. Sci. Signal. 3, ra54
48. 1 R heteromerization reveals a new mechanism for the pathogenic properties of angiotensin II. EMBO J. 30, 2350-2363
49. Smith, N. J., and Milligan, G. (2010) Allostery at G protein-coupled receptor homo- and heteromers. Uncharted pharmacological landscapes. Pharmacol. Rev. 62, 701-725
50. Maurice, P., Kamal, M., and Jockers, R. (2011) Asymmetry of GPCR oligomers supports their functional relevance. Trends Pharmacol. Sci. 32, 514-520
51. 1 receptor heterodimerization results in both ligand-dependent and -independent coordinated alterations of receptor localization and function. J. Biol. Chem. 281, 38812-38824
52. Liu, X. Y., Liu, Z. C., Sun, Y. G., Ross, M., Kim, S., Tsai, F. F., Li, Q. F., Jeffry, J., Kim, J. Y., Loh, H. H., and Chen, Z. F. (2011) Unidirectional cross-activation of GRPR by MOR1D uncouples itch and analgesia induced by opioids. Cell 147, 447-458
53. Urizar, E., Yano, H., Kolster, R., Galés, C., Lambert, N., and Javitch, J. A. (2011) CODA-RET reveals functional selectivity as a result of GPCR heteromerization. Nat. Chem. Biol. 7, 624-630
54. 2 receptor mRNA. Brain Res. 564, 203-219
55. 2-like receptors in vivo. Neuropharmacology 51, 597-605
56. 2 dopamine receptors. Neuropharmacology 47, 860-872
57. 35S]thio)-triphosphate binding and antibody study. Mol. Pharmacol. 55, 564-574
58. Pascal, G., and Milligan, G. (2005) Functional complementation and the analysis of opioid receptor homodimerization. Mol. Pharmacol. 68, 905-915 (Pubitemid 41206047)
59. Milligan, G. (2009) G protein-coupled receptor heterodimerization. Contribution to pharmacology and function. Br. J. Pharmacol. 158, 5-14
60. Milligan, G. (2007) G protein-coupled receptor dimerisation. Molecular basis and relevance to function. Biochim. Biophys. Acta 1768, 825-835
61. Duthey, B., Caudron, S., Perroy, J., Bettler, B., Fagni, L., Pin, J. P., and Prézeau, L. (2002) A single subunit (GB2) is required for G-protein activation by the heterodimeric GABA(B) receptor. J. Biol. Chem. 277, 3236-3241 (Pubitemid 34953187)